Ready to get certified?
Free CDCES Coach App
Subscribe
eNewsletter
Download
Free Med Pocket Cards
Question of the Week – January 29th, 2019
According to the National Credentialing Board for Diabetes Educators, (NCBDE) the CDCES® Exam Content Outline will be updated starting July 1st, 2019.
To celebrate this update, we will be basing our 2019 Questions of the Week on this content outline. (See a snippet of the NCBDE content outline to the left or click on it to see the complete outline.)
Question of the Week – January 29th, 2019
These targeted questions are designed to help assess your knowledge on the topics critical to diabetes educators.
In addition, if you are preparing to take the exam, we strongly encourage you to go through each of these sub-categories and rate your knowledge on a scale of 1-5. Based on this self-assessment, spend the majority of your study time on the topic areas you are least comfortable with. This approach will help you become familiar with the exam content and to use your limited study time wisely.
Assessment of the Diabetes Continuum – Learning
For this question in this series, we focus on the Assessment Section, under learning. Here is the question that addresses learning goals and needs of the learner. Good luck!
To learn more about exam success, please join us live or watch now Free Preparing for CDCES® Webinar airing on Feb 1st, 2019.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
[yikes-mailchimp form=”1″]Question of the Week – January 22nd, 2019
According to the National Credentialing Board for Diabetes Educators, (NCBDE) the CDCES® Exam Content Outline will be updated starting July 1st, 2019.
To celebrate this update, we will be basing our 2019 Questions of the Week on this content outline. (See a snippet of the NCBDE content outline to the left or click on it to see the complete outline.)
Question of the Week – January 22nd, 2019
These targeted questions are designed to help assess your knowledge on the topics critical to diabetes educators.
In addition, if you are preparing to take the exam, we strongly encourage you to go through each of these sub-categories and rate your knowledge on a scale of 1-5. Based on this self-assessment, spend the majority of your study time on the topic areas you are least comfortable with. This approach will help you become familiar with the exam content and to use your limited study time wisely.
Assessment of the Diabetes Continuum – Learning
For this question in this series, we focus on the Assessment Section, under learning. Here is the question that addresses learning goals and needs of the learner. Good luck!
To learn more about exam success, please join us live or watch now Free Preparing for CDCES® Webinar airing on Feb 1, 2019.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
[yikes-mailchimp form=”1″]Question of the Week – January 15th, 2019
NEW! Question of the Week will now reflect the 2019 CDCES®* Exam Content Outline
According to the National Credentialing Board for Diabetes Educators, (NCBDE) the CDCES® Exam Content Outline will be updated starting July 1st, 2019.
To celebrate this update, we will be basing our 2019 Questions of the Week on this content outline. (See a snippet of the NCBDE content outline to the left or click on it to see the complete outline.)
Question of the Week – January 15th, 2019
These targeted questions are designed to help assess your knowledge on the topics critical to diabetes educators.
In addition, if you are preparing to take the exam, we strongly encourage you to go through each of these sub-categories and rate your knowledge on a scale of 1-5. Based on this self-assessment, spend the majority of your study time on the topic areas you are least comfortable with. This approach will help you become familiar with the exam content and to use your limited study time wisely.
Assessment of the Diabetes Continuum – Learning
For this first question in this series, we start in the Assessment Section, under learning. Here is the question that addresses learning goals and needs of the learner. Good luck!
ML has a 6-year-old daughter with newly diagnosed type 1. ML wants to learn what to do in case her daughter gets the flu and is vomiting. What is the diabetes educator’s best response?
a. It sounds like you are worried about what to do if your daughter gets sick.
b. Let’s start with the basics of meal planning first.
c. Getting the flu can be scary. Have you been tracking ML’s blood sugars?
d. Here is a handout that reviews sick day management in detail.
Question of the Week – January 15th, 2019
To learn more about exam success, please join us live or watch now Free Preparing for CDCES® Webinar airing on Feb 1, 2019.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
[yikes-mailchimp form=”1″]Question of the Week | January 8th, 2019
NEW QUESTION OF THE WEEK!
Click here to take the question of the week >> January 8th, 2019
Are you wondering how to apply the newly released American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) Management of Hyperglycemia Guidelines into practice?
Meds Update – New ADA and EASD Guidelines – 1.5 CEs – webinar is now available!
You can also download our free CDCES Coach App!
Special Election Day Question of the Week!
Special Election Day Question of the Week – today you get to vote twice!
- In the Midterm Elections.
- Best answer for our Question of the Week!
Click here to take the question of the week >> November 6th, 2018!
Our Diabetes Detective Team scans the diabetes news to discover the most relevant info that Diabetes Educators need in their daily practice. We post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
Sign Up for Diabetes Blog Bytes Today
Do you know the best way to prepare for the CDCES exam? Want more questions like this? Really test your knowledge and prepare with our 1-Year Subscription, with over 34 online courses and 49.35 CEs.
You can also download our free CDCES Coach App!
Question of the Week – CV Disease and Diabetes
Test your knowledge by clicking here.
This weeks question reflects the new ADA Guidelines for Cardiovascular Disease and Diabetes.
And we invite you to join our newly updated webinar on this important and critical topic.
Cardiovascular Disease and Diabetes – 1.5 CE, individual price $29.00 Recorded July 2018. Ready for OnDemand Viewing.
Want to learn more about the current standards for Diabetes and CV Disease? This course takes a close look at insulin resistance syndrome and vascular complications. We discuss the impact of vessel disease from the heart to the toes. Included is a discussion of identifying and preventing vascular disease and the goals of care.
Cardiovascular Disease Management- American Diabetes Association Standard of Care – Jan 2018
Lower Extremity Information
Plant Based Eating Resources
Question of the Week Rationale – January
Question of the Week & Rationale
Our “Question of the Week” is created weekly by Coach Beverly to cover a variety of Diabetes related topics. The questions are designed to keep you current and prepare you for the CDCES® Exam.
To sign up to receive the question of the week, download our free CDCES Coach App or join our Facebook Page.
This week’s Rationale: Question of the Week – January 23rd – test your knowledge before seeing answer below!
What a perfect way to information share and bring new concepts to light. We appreciate our community of diabetes educators and the opportunity to keep learning together!
Question:
A new biosimilar insulin, lispro (Admelog) is now FDA Approved. Which of the following statement is true about biosimilar insulins?
a. Biosimilar has the same meaning as generic
b. Biosimilar means that the product is highly similar
c. Biosimilar means the structure is slightly different, but the function is similar
d. Biosimilar means the function is slightly different, but the structure is similar
Correct Answer: b. Biosimilar means that the product is highly similar
Rationale: As the patents expire on our commonly used insulins, plan to see more biosimilar insulin products on the market. Since these biosimilar insulins are usually priced more competitively, expect to see insurance companies transferring patients to these less expensive insulins. Patients may feel uncomfortable with this change and providing them with information on bio similarity standards may help ease concerns. Below are excerpts from the FDA Website on the definition of biosimilar and highly similar.
What is a biosimilar product?
A biosimilar is a biological product that is highly similar to and has NO clinically meaningful differences from an existing FDA-approved reference product.
What does it mean to be “highly similar”?
Minor differences between the reference product and the proposed biosimilar product in clinically inactive components are acceptable. For example, these could include minor differences in the stabilizer or buffer compared to what is used in the reference product. Any differences between the proposed biosimilar product and the reference product are carefully evaluated by FDA to ensure the biosimilar meets FDA’s high approval standards.
A manufacturer developing a proposed biosimilar demonstrates that its product is highly similar to the reference product by extensively analyzing (i.e., characterizing) the structure and function of both the reference product and the proposed biosimilar. State-of-the-art technology is used to compare characteristics of the products, such as purity, chemical identity, and bioactivity. The manufacturer uses results from these comparative tests, along with other information, to demonstrate that the biosimilar is highly similar to the reference product.
As mentioned above, slight differences (i.e., acceptable within-product variations) are expected during the manufacturing process for biological products, regardless of whether the product is a biosimilar or a reference product. For both reference products and biosimilars, lot-to-lot differences (i.e., acceptable within-product differences) are carefully controlled and monitored.
Read more about this on the FDA Website
Download our updated FREE Injectables PocketCard
Or join our Medication Update webinar!
Meds Update 2018– Earn 1.5 CE – $29
Live webinar session February 19th, 2018 at 11:30 a.m. – 1:15 p.m. PST
Feeling overwhelmed by all the new recently approved diabetes medications? Two bio-similiar insulins are now available and another GLP-1 RA was just approved. Plus, 2 new combo oral meds are now available.
If you want cutting edge information on the latest pharmacology and hospital glucose management, we highly recommend this Meds Update.
Question of the Week Rationale – Jan 19th
Question of the Week & Rationale
Our “Question of the Week” is created weekly by Coach Beverly to cover a variety of Diabetes related topics. The questions are designed to keep you current and prepare you for the CDCES® Exam.
To sign up to receive the question of the week, download our free CDCES Coach App or join our Facebook Page.
This week’s Rationale: Question of the Week – January 16th – test your knowledge before seeing answer below!
What a perfect way to information share and bring new concepts to light. We appreciate our community of diabetes educators and the opportunity to keep learning together!
Question:
Semaglutide (Ozempic) is a newly approved GLP-1 Receptor Agonist with a few unique features. Which of the following statements is true about Semaglutide (Ozempic)?
- It is available as an oral medication or injectable
- It reduces A1c less than other GLP-1 RAs
- It is associated with greater weight loss than other GLP-1 RAs
- It can be administered via pump
Correct Answer: c. It is associated with greater weight loss than other GLP-1 RAs
Rationale: Semaglutide (Ozempic,) as an adjunct to diet and exercise for the treatment of type 2 diabetes in adults.
Currently only available as an injection, this once weekly (GLP-1) receptor agonist will be available in 0.5-mg and 1.0-mg doses, via a dedicated prefilled pen device.
Semaglutide might be more effective than some of its competitors. In the five SUSTAIN efficacy trials, semaglutide reduced hemoglobin A1c by 1.5 to 1.8 percentage points. And, Semaglutide was associated with a 4.5- to 6.4-kg weight loss, more than the other available GLP-1 RAs.
For more info:
Download our updated FREE Injectables PocketCard
Or join our Medication Update webinar!
Meds Update 2018– Earn 1.5 CE – $29
Live webinar session February 19th, 2018 at 11:30 a.m. – 1:15 p.m. PST
Feeling overwhelmed by all the new recently approved diabetes medications? Two bio-similiar insulins are now available and another GLP-1 RA was just approved. Plus, 2 new combo oral meds are now available.
If you want cutting edge information on the latest pharmacology and hospital glucose management, we highly recommend this Meds Update.
